SCHEMBL6167443

SCHEMBL6167443

N#Cc1cccc(CNC(=O)c2ccccc2-c2cccc(C#N)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.60
▸ CHRNA4 P43681 2/20 0.60
▸ CHRNB4 P30926 1/20 0.60
▸ CHRNA3 P32297 1/20 0.60
▸ HTT P42858 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ CHRM3 P20309 3/20 0.50
▸ ERCC1 P07992 1/20 0.49
▸ ERCC4 Q92889 1/20 0.49
▸ KLKB1 P03952 1/20 0.48
▸ KLK1 P06870 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ ROCK2 O75116 2/20 0.47
▸ ROCK1 Q13464 1/20 0.47
▸ HDAC7 Q8WUI4 2/20 0.46
▸ NAMPT P43490 1/20 0.46
▸ HDAC1 Q13547 1/20 0.45
▸ VNN1 O95497 1/20 0.45
▸ CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182120 0.91 CHRNB2 (0.59) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6161708 0.91 CHRNB2 (0.59) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL18132544 0.83 KMT2A (0.66) HTTKMT2AERCC1ERCC4KLKB1
SCHEMBL15606149 0.81 CHRNB2 (0.74) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL13635582 0.80 ERCC1 (0.49) HTTKMT2ACHRM3ERCC1ERCC4
SCHEMBL6164524 0.79 CHRNB2 (0.67) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL9365904 0.79 MAOA (0.66) CHRM3ERCC1ERCC4MAOAROCK2
SCHEMBL5085509 0.77 SLC22A12 (0.61) HTT
SCHEMBL25374278 0.76 POLB (0.57) KMT2ACHRM3ERCC1ERCC4KLKB1
SCHEMBL20703692 0.76 BCAT2 (0.59) HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 — — EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 — — US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 — — EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI CHRNB2 4636/4885CHRNA4 4237/4885CHRNB4 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback